Juan Carlos Redondo-González

Mr. Juan Carlos Redondo-González

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Precision Cancer Medicine
Verified
Journal Article
Open access
PDF file
Alejandro Olivares-HernándezAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
LPLuis Posado-Domínguez
Luis Posado-Domínguez
MMMaría Martín-Galache
María Martín-Galache
Juan Carlos Redondo-GonzálezJuan Carlos Redondo-González
Juan Carlos Redondo-González
JRJonnathan Roldán-Ruiz
Jonnathan Roldán-Ruiz
EBEdel del Barco-Morillo
Edel del Barco-Morillo
Background and Objective: The implementation in routine clinical practice of PD-L1 expression analysis and new massive sequencing techniques (NGS) has resulted in the creation of a molecular classification that leads on the most appropriate treatment for non-small cell lung cancer (NSCLC) is decided. Nowadays, specific treatments approved first-line against different mutations such as those targeting the EGFR, ALK, ROS1, KRAS, BRAF, RET or MET genes are commercially available. In this literature review we analyze the importance of the KRAS oncogene as a clinical biomarker in patients with NSCLC, its implication as a predictor of response to immunotherapy and the difficulties in developing specific drugs that act against mutations in this oncogene. Methods: The narrative review was conducted and carried out using the quality standards of narrative or literature review current guidelines. The reviews, clinical trials and studies included were found through searching several databases: PubMed, Cochrane, Science Direct, EMBASE, and the clinical trial registry (www.clinicaltrials.gov). The studies reviewing the main clinical trials that resulted in the approval of targeted therapies in NSCLC KRAS mutated and then the immunotherapy treatment in this type of lung cancer. Key Content and Findings: KRAS oncogene is one of the most frequently altered oncogenes in human cancers. In NSCLC it is altered in 20–30% of cases. In recent years, the identification of a new allosteric binding site in KRAS G12C has allowed the development of irreversible covalent inhibitors that have demonstrated their efficacy in daily clinical practice. However, other frequent mutations such as KRAS G12D and KRAS G12V still lack approved drugs although promising results have already been obtained in in-vitro and in-vivo clinical trials. There also appears to be a greater efficacy of response to immunotherapy in KRAS-mutated NSCLC, although this is a field under study. Conclusions: The KRAS gene has fundamental implications in NSCLC, both at the molecular and clinical levels. The correct and thorough characterisation of the different alterations and mutations of the KRAS gene will open up new avenues in the treatment of KRAS-mutated NSCLC, as well as personalising immunotherapy treatments in patients with these alterations.

5 December 2025 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
Juan Carlos Redondo-GonzálezJuan Carlos Redondo-González
Juan Carlos Redondo-González
JCJuan Carlos
Juan Carlos
LPLuis Posado-Domínguez
Luis Posado-Domínguez
LCLaura Corvo-Félix
Laura Corvo-Félix
LBLorena Bellido
Lorena Bellido
EBEDEL DEL BARCO-MORILLO
EDEL DEL BARCO-MORILLO

1 October 2025 in Chinese Clinical Oncology
Verified
Journal Article
Open access
PDF file
Juan Carlos Redondo-GonzálezJuan Carlos Redondo-González
Juan Carlos Redondo-González
LPLuis Posado-Domínguez
Luis Posado-Domínguez
LCLaura Corvo-Félix
Laura Corvo-Félix
JMJosé Pablo Miramontes-González
José Pablo Miramontes-González
EFEmilio Fonseca-Sánchez
Emilio Fonseca-Sánchez
AOAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
Background and Objective: Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) represents 80–85% of cases, with 20–35% diagnosed at stage III. Stage III NSCLC is highly heterogeneous, encompassing both resectable and unresectable disease. The aim of this article is to review current evidence on the treatment of stage III NSCLC, with a focus on neoadjuvant chemoimmunotherapy (CT-IO) vs. the standard of chemoradiotherapy (CT/RT) followed by consolidation immunotherapy. Methods: The narrative review was conducted and carried out using clinical trials and studies included were found through searching several databases: PubMed, Cochrane, Science Direct, EMBASE, and the clinical trial registry (www.clinicaltrials.gov). Key Content and Findings: Historically, concurrent CT/RT followed by 1 year of durvalumab has been the standard for unresectable stage III disease, as demonstrated in the PACIFIC trial. The introduction of CT-IO neoadjuvant regimens has shown improved outcomes in stage IIIA and IIIB disease, particularly in terms of pathological complete response (pCR), event-free survival (EFS), and overall survival (OS). Clinical trial heterogeneity regarding tumor-node-metastasis (TNM) staging, patient selection, and adjuvant therapy duration limits direct comparisons. However, emerging data suggest that CT-IO could become a new standard for stage IIIA and selected IIIB/IIIC patients. Neoadjuvant CT-IO represents a significant shift in the treatment paradigm of stage III NSCLC, offering personalized and potentially more effective therapeutic options. Conclusions: While CT/RT remains essential for certain subsets, particularly T4 or unresectable tumors, CT-IO should be strongly considered for most patients with stage IIIA and IIIB NSCLC.

13 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Gema Barrientos VichoGema Barrientos Vicho
Gema Barrientos Vicho
LPLuis Posado-Domínguez
Luis Posado-Domínguez
JUJosé David Urchaga
José David Urchaga
LFLuis Figuero-Perez
Luis Figuero-Perez
FVF. Javier Alves Vas
F. Javier Alves Vas
CSCesar Augusto Rodríguez Sánchez
Cesar Augusto Rodríguez Sánchez
Objective: Physical exercise is an effective supportive strategy in oncology, yet its implementation remains limited, particularly in patients with metastatic breast cancer. This prospective pilot program aimed to evaluate the effects of a 12-week supervised multicomponent exercise program on quality of life, functional capacity, and biological parameters in women undergoing treatment for breast cancer. Methods: Prospective single-arm pilot program. In total, 44 women with early or metastatic breast cancer were enrolled; 29 completed the full intervention and assessments. The program consisted of supervised aerobic, resistance, mobility, and neuromuscular training three times per week. Quality of life was assessed using the EORTC QLQ-C30 questionnaire. Strength, body composition, functional mobility (Functional Movement Screen, FMS), 6 min walk test (6MWT), and laboratory markers (RDW, HDL, and cholesterol profile) were evaluated pre- and post-intervention. Results: Significant improvements were observed in global quality of life (+19.5%, p = 0.002), physical function (p = 0.006), emotional function (p = 0.003), and fatigue reduction (p = 0.007). The FMS total score increased significantly (p = 0.001), and 6MWT distance improved by 110 m (p < 0.001). Biochemical analyses showed a significant reduction in RDW (p = 0.005), a pro-inflammatory marker, and an increase in HDL cholesterol (p = 0.007). The intervention was well tolerated, with no exercise-related serious adverse events and high adherence to the supervised program. Conclusions: A 12-week supervised exercise program is feasible and beneficial for women with breast cancer, including those with metastatic disease. It is associated with improvements in quality of life, functional mobility, and selected markers of systemic inflammation. These findings should be considered exploratory and support the integration of structured exercise into routine oncologic care, pending confirmation in larger controlled studies.

19 March 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Juan Carlos Redondo-GonzálezJuan Carlos Redondo-González
Juan Carlos Redondo-González
IMIñigo San Miguel
Iñigo San Miguel
MGMarta Rodríguez González
Marta Rodríguez González
JMJuan Carlos Montero
Juan Carlos Montero
JSJose María Sayagués
Jose María Sayagués
Alejandro Olivares-HernándezAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
Background: The development of advanced genomic sequencing techniques now makes it possible to identify novel biomarkers and guide the design of targeted therapeutic strategies. For advanced squamous non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) fusions have not been evaluated as a therapeutic target. However, agents that block the pathway activated by these fusions have shown efficacy in other solid tumors, such as melanoma, astrocytoma, acinar carcinoma of the pancreas, and papillary thyroid tumors. Case Report: Here, we present the case of a patient with locally advanced squamous NSCLC and minimal smoking history who was found to harbor a TMEM178B::BRAF fusion. Following curative-intent chemoradiotherapy (CRT) and subsequent maintenance immunotherapy, the patient achieved a complete radiological response at 12 months, accompanied by a marked improvement in both quality of life and overall clinical status. Conclusions: The findings in this patient underscore the importance of extending molecular genetic studies to patients with squamous histology who lack toxic habits or known risk factors. Gene alterations such as BRAF rearrangements may not only predict the response to immunotherapy-based treatments but also represent a promising avenue for the development of new therapeutic strategies.